Hypercapnic patients were best separated from normocapnic patients using thresholds for FVC% of 56% predicted and 33% predicted for FEV1%. Hypercapnia in patients with chronic obstructive pulmonary ...
Supported by an independent educational grant from Boehringer Ingelheim and Pfizer. Mrs. Sweet is a 51-year-old woman who presents to your office with the chief complaint of shortness of breath and ...
Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID 1) and deupirfenidone 825 mg TID and successfully demonstrated ...
Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo. Bexotegrast was well tolerated at 160 mg over 12 weeks of ...
Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.
Background The relationship of social determinants of health (SDOH), environmental exposures and medical history to lung function trajectories is underexplored. A better understanding of these ...
Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need ...
If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback